PEBP1 Monoklonaler Antikörper

PEBP1 Monoklonal Antikörper für IF/ICC

Wirt / Isotyp

Maus / IgG1

Getestete Reaktivität

human, Maus, Ratte

Anwendung

IF/ICC

Konjugation

CoraLite®594 Fluorescent Dye

CloneNo.

2D4D11

Kat-Nr. : CL594-66438

Synonyme

HCNP, HCNPpp, Neuropolypeptide h3, PBP, PEBP, PEBP 1, PEBP1, Prostatic binding protein, Raf kinase inhibitor protein, RKIP

---

• 

  IF Staining of A549 using CL594-66438

  Immunofluorescent analysis of (-20°C Ethanol) fixed A549 cells using CoraLite®594 PEBP1 antibody (CL594-66438, Clone: 2D4D11 ) at dilution of 1:200.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in IF/ICC: A549-Zellen

Empfohlene Verdünnung

• Immunfluoreszenz (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

CL594-66438 bindet in IF/ICC PEBP1 und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• Wirt / Isotyp: Maus / IgG1
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: PEBP1 fusion protein Ag0864
• Vollständiger Name: phosphatidylethanolamine binding protein 1
• Berechnetes Molekulargewicht: 21 kDa
• Beobachtetes Molekulargewicht: 23-27 kDa
• GenBank-Zugangsnummer: BC008714
• Gene symbol: PEBP1
• Gene ID (NCBI): 5037
• Konjugation: CoraLite®594 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 588 nm / 604 nm
• Form: Liquid
• Reinigungsmethode: Protein-G-Reinigung
• Lagerungspuffer: PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Raf kinase inhibitor protein (RKIP), also termed phosphatidylethanolamine binding protein PEBP1, was initially identified as a potent inhibitor of Raf-1/MEK/ERK, NF-kB, and G-protein-coupled receptor signaling pathways. Later RKIP has been further identified as a metastasis suppressor and its loss of expression has been reported in various cancers. Its expression has been proposed as a prognostic marker for patients diagnosed with the above cancers.